The Technical Analyst
Cytosorbents Corp [CTSO]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Cytosorbents Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.55% $0.809
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 43.92 mill |
| EPS: | -0.640 |
| P/E: | -1.260 |
| Earnings Date: | Apr 30, 2024 |
| SharesOutstanding: | 54.29 mill |
| Avg Daily Volume: | 0.102 mill |
| RATING 2024-04-25 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.260 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -1.260 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.739 - 0.879 ( +/- 8.65%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-02 | Jones Edward Raymond | Buy | 22 000 | Stock Option (Right to Buy) |
| 2024-04-02 | Deliargyris Efthymios | Buy | 61 000 | Common Stock |
| 2024-04-02 | Deliargyris Efthymios | Buy | 86 000 | Stock Option (Right to Buy) |
| 2024-04-02 | Sobel Alan D. | Buy | 22 000 | Stock Option (Right to Buy) |
| 2024-04-02 | Bloch Kathleen P. | Buy | 65 000 | Common Stock |
| INSIDER POWER |
|---|
| 77.75 |
| Last 100 transactions |
| Buy: 4 191 625 | Sell: 429 500 |
Forecast:
16:00 - $0.810
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.810
Forecast 2: 16:00 - $0.810
Forecast 3: 16:00 - $0.810
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.809 (-1.55% ) |
| Volume | 0.0464 mill |
| Avg. Vol. | 0.102 mill |
| % of Avg. Vol | 45.41 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CTSO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CTSO
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Last 10 Buy Signals
| Date | Signal | @ |
|---|---|---|
| RARIUSD | Apr 26 - 07:07 | 3.90 |
| FLUXUSD | Apr 26 - 07:05 | $0.887 |
| AUTO.OL | Apr 26 - 06:52 | NOK16.64 |
| SCATC.OL | Apr 26 - 06:50 | NOK73.20 |
| NEXOUSD | Apr 26 - 07:03 | 1.210 |
| PEXIP.OL | Apr 26 - 06:30 | NOK26.85 |
| ANKRETHUSD | Apr 26 - 07:02 | 3 588.86 |
| FRXETHUSD | Apr 26 - 06:59 | 3 117.57 |
| AGLX.OL | Apr 26 - 06:46 | NOK29.80 |
| NAS.OL | Apr 26 - 06:46 | NOK15.06 |
Latest Press Releases
2024-04-26 07:00:00 - Press Release
Cytosorbents To Report First Quarter 2024 Operating And Financial Results
Princeton, n.j., april 26, 2024 (globe newswire) -- cytosorbents corporation (nasdaq: ctso), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2024 operating and financial results after the market close on thursday, may 9th, 2024.
2024-04-17 07:00:00 - Press Release
Star-t Pivotal Trial Results To Be Featured As A Late-breaking Presentation At The 2024 American Association For Thoracic Surgery Annual Meeting
Princeton, n.j., april 17, 2024 (globe newswire) -- cytosorbents corporation (nasdaq: ctso), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that topline results from its pivotal u.s. and canadian safe and timely antithrombotic removal of ticagrelor (star-t) randomized controlled trial will be featured as a late-breaking clinical trial presentation at the 104th annual meeting of the american association for thoracic surgery (aats), taking place friday, april 26 through tuesday, april 30, 2024 in toronto, on, canada.details of the star-t presentation are as follows: 104 th american association for thoracic surgery annual meeting session: adult cardiac scientific session: trials and trends title: a pivotal randomized, sham-controlled trial examining the safety and efficacy of intraoperative removal of ticagrelor in patients undergoing urgent cardiac surgery presenter: michael j.
2024-03-14 16:39:00 - Press Release
Cytosorbents Reports Fourth Quarter And Full Year 2023 Results
Star-t trial results selected for a breakout presentation at the american association of thoracic surgery annual meeting in late-april 2024 cytosorbents intends to submit drugsorb-atr for regulatory approval to u.s. food & drug administration (fda) and health canada this year cytosorb core sales increased approximately 10% year-over-year 2023 product gross margins increased to 72% cumulative cytosorb treatments surpassed 228,000 princeton, n.j., march 14, 2024 (globe newswire) -- cytosorbents corporation (nasdaq: ctso), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today reported financial and operating results for the quarter and year ended december 31, 2023 and provides its 2024 outlook.
2024-03-06 07:00:00 - Press Release
Cytosorbents To Report Fiscal 2023 Operating And Financial Results
Princeton, n.j., march 06, 2024 (globe newswire) -- cytosorbents corporation (nasdaq: ctso), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fiscal 2023 financial results on thursday, march 14th, 2024 at 4:30pm edt.
2024-02-08 07:00:00 - Press Release
Cytosorbents To Present At The Td Cowen 44th Annual Health Care Conference
Princeton, n.j., feb. 08, 2024 (globe newswire) -- cytosorbents corporation (nasdaq: ctso), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that dr. phillip chan, chief executive officer, will present at the td cowen 44 th annual health care conference at the boston marriott copley place, in boston, ma on wednesday, march 6th, 2024.
Latest News
2024-04-26 07:00:00 - GlobeNewsWire
CytoSorbents to Report First Quarter 2024 Operating and Financial Results
PRINCETON, N.J., April 26, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2024 operating and financial results after the market close on Thursday, May 9th, 2024.
2024-03-14 22:24:03 - Seeking Alpha
CytoSorbents Corporation (CTSO) Q4 2023 Earnings Call Transcript
2024-03-06 07:00:00 - GlobeNewsWire
CytoSorbents to Report Fiscal 2023 Operating and Financial Results
PRINCETON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fiscal 2023 financial results on Thursday, March 14th, 2024 at 4:30PM EDT.
2023-11-09 22:06:01 - Seeking Alpha
Cytosorbents Corporation (CTSO) Q3 2023 Earnings Call Transcript
2023-10-27 07:00:00 - GlobeNewsWire
CytoSorbents to Report Third Quarter 2023 Operating and Financial Results
PRINCETON, N.J., Oct. 27, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2023 operating and financial results after the market close on Thursday, November 9th, 2023.
2023-08-01 21:25:04 - Seeking Alpha
Cytosorbents Corporation (CTSO) Q2 2023 Results Earnings Conference Call
Cytosorbents Corporation. (NASDAQ:CTSO ) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Taylor Devlin - Revenue Accountant Phillip Chan - Chief Executive Officer Vincent Capponi - President and Chief Operating Officer Kathleen Bloch - Interim Chief Financial Officer Efthymios Deliargyris - Chief Medical Officer Christopher Cramer - Senior Vice President of Business Development Irina Kulinets - Senior Vice President of Regulatory Conference Call Participants Joshua Jennings - TD Cowen Laura Suriel - Alliance Global Partners Sean Lee - H.C.
2023-07-26 07:00:00 - GlobeNewsWire
CytoSorbents to Report Second Quarter 2023 Operating and Financial Results
PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2023 operating and financial results after the market close on Tuesday, August 1st, 2023. CytoSorbents' management will host a live presentation webcast and a question and answer session at 4:30PM EDT the same day.
2023-05-02 22:11:03 - Seeking Alpha
Cytosorbents Corporation (CTSO) Q1 2023 Earnings Call Transcript
Cytosorbents Corporation (NASDAQ:CTSO ) Q1 2023 Results Earnings Conference Call May 2, 2023 4:30 AM ET Company Participants Taylor Devlin - Revenue Accountant Phillip Chan - Chief Executive Officer Kathleen Bloch - Interim Chief Financial Officer Efthymios Deliargyris - Chief Medical Officer Christian Steiner - Executive Vice President of Sales and Marketing Conference Call Participants Thomas Kerr - Zacks Investment Research Sean Lee - H.C. Wainwright & Co. Operator Good afternoon and welcome to the Cytosorbents First Quarter 2023 Financial and Operating Results Conference Call.
2023-03-09 23:32:06 - Seeking Alpha
Cytosorbents Corporation (CTSO) Q4 2022 Earnings Call Transcript
Cytosorbents Corporation (NASDAQ:CTSO ) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Company Participants Jodi Hoover – Manager-Clinical Administration Phillip Chan – Chief Executive Officer Irina Kulinets – Senior Vice President-Global Regulatory Kathleen Bloch – Chief Financial Officer Efthymios Deliargyris – Chief Medical Officer Vincent Capponi – President and Chief Operating Officer Christian Steiner – Executive Vice President-Sales and Marketing and Managing Director-CytoSorbents Europe GmbH Conference Call Participants Mike Sarcone – Jefferies Josh Jennings – TD Cowen Sean Lee – H.C. Wainwright Tom Kerr – Zacks Investment Research Operator Good afternoon, and welcome to the Cytosorbents Fourth Quarter and Full Year 2022 Financial and Operating Results Conference Call.
2023-02-24 07:00:00 - PRNewsWire
CytoSorbents to Report Fiscal 2022 Operating and Financial Results
MONMOUTH JUNCTION, N.J. , Feb. 24, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fiscal 2022 financial results on Thursday, March 9, 2023 at 4:30PM EST.